Shares of Zoetis Inc (NYSE:ZTS) have earned an average recommendation of “Buy” from the eighteen brokerages that are covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $93.60.
A number of equities analysts have issued reports on ZTS shares. Zacks Investment Research downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a report on Friday, October 5th. Argus set a $105.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a report on Tuesday, November 13th. BMO Capital Markets reaffirmed a “hold” rating on shares of Zoetis in a report on Sunday, November 11th. JPMorgan Chase & Co. lifted their price objective on shares of Zoetis from $100.00 to $101.00 and gave the stock an “overweight” rating in a report on Friday, November 2nd. Finally, Morgan Stanley set a $100.00 price objective on shares of Zoetis and gave the stock a “hold” rating in a report on Friday, November 2nd.
In related news, EVP Roxanne Lagano sold 2,000 shares of the business’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $85.30, for a total value of $170,600.00. Following the sale, the executive vice president now directly owns 22,023 shares in the company, valued at approximately $1,878,561.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Heidi C. Chen sold 2,500 shares of the business’s stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $93.51, for a total value of $233,775.00. Following the completion of the sale, the insider now owns 17,662 shares in the company, valued at $1,651,573.62. The disclosure for this sale can be found here. Insiders have sold a total of 171,511 shares of company stock worth $16,238,439 over the last quarter. Company insiders own 0.35% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Clarus Wealth Advisors bought a new stake in shares of Zoetis during the fourth quarter valued at about $231,000. CENTRAL TRUST Co increased its position in shares of Zoetis by 18.3% during the fourth quarter. CENTRAL TRUST Co now owns 32,379 shares of the company’s stock valued at $2,770,000 after buying an additional 5,001 shares during the period. North Star Investment Management Corp. increased its position in shares of Zoetis by 0.6% during the fourth quarter. North Star Investment Management Corp. now owns 22,525 shares of the company’s stock valued at $1,927,000 after buying an additional 125 shares during the period. Park National Corp OH increased its position in shares of Zoetis by 150.3% during the fourth quarter. Park National Corp OH now owns 85,542 shares of the company’s stock valued at $7,317,000 after buying an additional 51,370 shares during the period. Finally, Martingale Asset Management L P grew its holdings in shares of Zoetis by 2.6% during the third quarter. Martingale Asset Management L P now owns 11,821 shares of the company’s stock worth $1,083,000 after purchasing an additional 300 shares in the last quarter. Hedge funds and other institutional investors own 89.86% of the company’s stock.
NYSE ZTS opened at $86.54 on Friday. Zoetis has a 12-month low of $70.20 and a 12-month high of $96.57. The company has a debt-to-equity ratio of 3.04, a current ratio of 4.06 and a quick ratio of 2.63. The firm has a market capitalization of $40.72 billion, a P/E ratio of 36.06, a price-to-earnings-growth ratio of 1.50 and a beta of 1.01.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, November 1st. The company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.06. Zoetis had a net margin of 20.35% and a return on equity of 75.51%. The business had revenue of $1.48 billion during the quarter, compared to the consensus estimate of $1.46 billion. During the same quarter last year, the firm posted $0.65 EPS. Zoetis’s revenue was up 9.9% compared to the same quarter last year. On average, sell-side analysts expect that Zoetis will post 3.11 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 1st. Stockholders of record on Friday, January 18th will be paid a dividend of $0.164 per share. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.76%. This is a boost from Zoetis’s previous quarterly dividend of $0.13. The ex-dividend date of this dividend is Thursday, January 17th. Zoetis’s payout ratio is presently 20.83%.
Zoetis announced that its board has approved a share buyback program on Wednesday, December 12th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the company to purchase up to 4.7% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Article: What is a back-end load?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.